Editor’s Note: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer being the most common molecular subtype. In recent years, targeted therapies, antibody-drug conjugates (ADCs), and selective estrogen receptor degraders (SERDs) have propelled this subtype into the era of precision medicine. Looking back at 2024, what breakthroughs and conceptual shifts have occurred in the systemic treatment of HR+/HER2- breast cancer? Oncology Frontier invited Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences and the Chinese Academy of Engineering to provide an overview and summary.

In 2024, significant progress was made in the field of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), bringing new insights and advancements to clinical practice. These studies covered innovations in treatment approaches, evaluations of drug efficacy, and a deeper understanding of the biological characteristics of these diseases. These findings are crucial for advancing precision medicine in pediatric leukemia and improving patient outcomes.

In 2024, the field of chronic myeloid leukemia (CML) witnessed significant breakthroughs in research and clinical advancements. From the development of novel therapeutic agents to the optimization of treatment strategies, from studies on treatment discontinuation to deeper explorations into disease mechanisms, these findings have expanded treatment options and brought new hope to patients. As we step into the new year, Hematology Frontier has invited Dr. Qian Jiang from Peking University People's Hospital to review the key research progress in CML over the past year, particularly focusing on breakthrough findings presented at the ASH and EHA Annual Meetings. Additionally, Jiang shares insights from her team’s clinical experience in CML management and offers a perspective on future directions, aiming to provide new insights for clinical practice and long-term patient care strategies.